ArticleJournal of animal science2026
Plant-derived betaine enhances barrier integrity and immune responses in canine intestinal epithelial cells and macrophages under endotoxin challenge.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Strain-Specific Effects ofMicroorganisms · 2026Article
- Barrier and Immune Modulation byInternational journal of molecular sciences · 2026Article
- Functional Effects ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in the utilization of novel plant-based extracts for supporting gut health and nutrition in companion animals is growing. The effect of betaine on canine intestinal barrier integrity and immune-related gene and protein expression by epithelial and macrophage-like cells was evaluated under conditions of inflammatory challenge from lipopolysaccharide (LPS). We evaluated: (1) the effect of betaine pre-treatment (0 to 1,000 µg/mL for 24 h) on the viability of canine intestinal epithelial MCA-B1 and macrophage-like DH82 cells; (2) epithelial barrier function of LPS-challenged MCA-B1 cells pre-treated with betaine, by measurement of 4-kDa fluorescein isothiocyanate (FITC-dextran [FD4] flux); (3) gene and protein expression of tight junction proteins and adhesion molecules using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and proteomics; (4) anti- and pro-inflammatory and regulatory gene expression in LPS-challenged, betaine pre-treated, MCA-B1, DH82 and peripheral blood mononuclear cells and; (5) the phagocytic activity of DH82 cells pre-treated with betaine. No cytotoxicity of betaine against MCA-B1 or DH82 cells were observed. Betaine pre-treatment of MCA-B1 reduced FD4 permeability compared with untreated cells (P < 0.05), accompanied by increased (mRNA) expression of claudin-1 (P < 0.001) and E-cadherin (P < 0.05) and increased protein expression of junctional adhesion molecules (P < 0.05), vinculin (P < 0.05) and aquaporin-3 (AQP3; P < 0.01). Betaine pre-treatment of LPS-challenged cells also increased the expression of regulatory cytokines TGF-β1 (P < 0.01), TGF-β2 (P < 0.01), and IL-33 (P < 0.05) in MCA-B1 cells and reduced the expression of IL-6 (P < 0.05) and MyD88 (P < 0.01) in DH82 cells compared with untreated cells. In addition, betaine enhanced the phagocytic activity of DH82 cells (P < 0.01) compared with untreated cells. Confirmatory studies in vivo are needed but these results suggest that plant-derived betaine has potential as a nutritional supplement for companion animals to support gut health and immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.